# Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)

> **NCT00552565** · PHASE3 · COMPLETED · sponsor: **AGI Therapeutics, Inc.** · enrollment: 711 (actual)

## Conditions studied

- Irritable Bowel Syndrome With Diarrhea

## Interventions

- **DRUG:** Rezular 15mg
- **DRUG:** Placebo
- **DRUG:** Rezular
- **DRUG:** Rezular

## Key facts

- **NCT ID:** NCT00552565
- **Lead sponsor:** AGI Therapeutics, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 711 (ACTUAL)
- **Last updated:** 2009-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00552565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00552565, "Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00552565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*